Dimension Therapeutics Reports Recent Corporate Progress and First Quarter 2016 Financial Results
May 12, 2016 09:00 ET
|
Dimension Therapeutics
Expanded inherited metabolic disease (IMD) portfolio; New programs address citrullinemia type 1, phenylketonuria (PKU), and Wilson disease Expect to file INDs for lead IMD product candidates,...
Dimension Therapeutics Announces Preclinical Data from Bayer-Partnered Hemophilia A Program at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
May 07, 2016 12:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., May 07, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies...
Dimension Therapeutics Announces Gene Therapy Research Collaboration with the University of Pennsylvania and Expansion of Inherited Metabolic Disease Portfolio
May 05, 2016 14:15 ET
|
Dimension Therapeutics
Therapeutic Programs Address Citrullinemia Type 1, Phenylketonuria, and Wilson Disease Diseases Can Have Devastating Consequences for Patients and Families, with Few Effective Treatment Options ...
Dimension Therapeutics Announces Preclinical Data Supporting Ongoing DTX101 Phase 1/2 Clinical Trial at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
May 05, 2016 08:00 ET
|
Dimension Therapeutics
Findings Demonstrated Dose-Dependent Durable Gene Expression, and No Apparent Safety Issues Across the Dose Range Tested Topline Data from First Cohort in Phase 1/2 Trial of DTX101 Expected in the...
Dimension Therapeutics Announces Participation in Two Upcoming Conferences
April 28, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
April 18, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., April 18, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics to Present at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference
April 06, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., April 06, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics Reports Recent Corporate Progress and Full Year 2015 Financial Results
March 24, 2016 09:10 ET
|
Dimension Therapeutics
- Treated first patients in phase I/II clinical study of DTX101 for hemophilia B - - Expect to file an IND and initiate dosing for DTX301 for OTC deficiency in second half 2016 - - Selected...
Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation for DTX301 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
March 17, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., March 17, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, liver-directed treatments for diverse rare diseases...
Dimension Therapeutics to Present at Two Upcoming Investor Conferences
March 01, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, liver-directed treatments for diverse rare diseases...